Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. George J. FennellExec. VP of Global CAG Commercial | -284,00 | 160,97k | Derivative Exercise and Sale | 566,79 | 10,43k | - |
| 2026-06-01 | Mr. George J. FennellExec. VP of Global CAG Commercial | 355,00 | 0,00 | Derivative Exercise and Retained Stock | - | 10,43k | 3,52% |
| 2026-05-07 | Mr. Joseph L. HooleyIndependent Director | 158,00 | 0,00 | Derivative Exercise and Retained Stock | - | 276,00 | 133,90% |
| 2026-05-07 | Mr. Daniel M. JuniusIndependent Director | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,56k | 7,78% |
| 2026-05-07 | Ms. Karen A. PeacockIndependent Director | 101,00 | 0,00 | Derivative Exercise and Retained Stock | - | 102,00 | 10.100,00% |
| 2026-05-07 | Mr. Lawrence D. KingsleyIndependent Lead Director | 339,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,57k | 4,12% |
| 2026-05-07 | Ms. M. Anne SzostakInsider | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,06k | 14,25% |
| 2026-05-07 | Dr. Sophie V. VandebroekIndependent Director | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,43k | 3,14% |
| 2026-03-03 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 197,00 | 99,59k | Derivative Exercise and Retained Stock | 505,53 | 7,14k | 2,84% |
| 2026-03-03 | Dr. Nimrata Khatra HuntAdvisor | -1,76k | 1,12M | Verkauf | 634,57 | 18,30k | -8,76% |
| 2026-02-27 | Mr. Jonathan J. MazelskyExecutive Chairman | 197,00 | 99,59k | Derivative Exercise and Retained Stock | 505,53 | 83,80k | 0,24% |
| 2026-02-26 | Mr. Jonathan J. MazelskyExecutive Chairman | -23,33k | 12,04M | Derivative Exercise and Sale | 141,60 - 663,04 | 83,80k | - |
| 2026-02-26 | Dr. Nimrata Khatra HuntAdvisor | -2,69k | 1,78M | Verkauf | 661,54 | 20,06k | -11,84% |
| 2026-02-17 | Dr. Sophie V. VandebroekIndependent Director | -945,00 | 278,53k | Derivative Exercise and Sale | 333,90 - 628,65 | 8,17k | - |
| 2026-02-17 | Dr. Sophie V. VandebroekIndependent Director | -519,00 | 326,22k | Verkauf | 628,56 | 8,17k | -5,97% |
| 2026-02-19 | Mr. Michael G. EricksonCEO, President & Director | 2,40k | 546,56k | Derivative Exercise and Retained Stock | 141,60 - 544,08 | 14,91k | 19,18% |
| 2026-02-17 | Mr. Michael G. EricksonCEO, President & Director | -5,37k | 2,46M | Derivative Exercise and Sale | 141,60 - 629,86 | 14,91k | - |
| 2026-02-14 | Dr. Nimrata Khatra HuntAdvisor | 1,43k | 0,00 | Derivative Exercise and Retained Stock | - | 22,75k | 6,72% |
| 2026-02-14 | Dr. Nimrata Khatra HuntAdvisor | -1,15k | 726,27k | Derivative Exercise and Sale | 629,35 | 22,75k | - |
| 2026-02-14 | Mr. Michael P. JohnsonExec. VP & Chief HR Officer | 395,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,80k | 16,46% |
| 2026-02-14 | Mr. Michael P. JohnsonExec. VP & Chief HR Officer | -178,00 | 112,02k | Derivative Exercise and Sale | 629,35 | 2,80k | - |
| 2026-02-14 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 871,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,25k | 11,81% |
| 2026-02-14 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | -221,00 | 139,09k | Derivative Exercise and Sale | 629,35 | 8,25k | - |
| 2026-02-14 | Mr. Michael SchreckExec. VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | 1,08k | 0,00 | Derivative Exercise and Retained Stock | - | 3,09k | 53,99% |
| 2026-02-14 | Mr. Michael SchreckExec. VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | -876,00 | 551,31k | Derivative Exercise and Sale | 629,35 | 3,09k | - |
| 2026-02-14 | Mr. Jonathan J. MazelskyExecutive Chairman | 1,14k | 0,00 | Derivative Exercise and Retained Stock | - | 83,61k | 1,38% |
| 2026-02-14 | Mr. Jonathan J. MazelskyExecutive Chairman | -915,00 | 575,86k | Derivative Exercise and Sale | 629,35 | 83,61k | - |
| 2026-02-14 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 581,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,94k | 9,14% |
| 2026-02-14 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | -251,00 | 157,97k | Derivative Exercise and Sale | 629,35 | 6,94k | - |
| 2026-02-14 | Mr. Martin Alderson SmithInsider | 702,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,16k | 48,25% |
| 2026-02-14 | Mr. Martin Alderson SmithInsider | -302,00 | 190,06k | Derivative Exercise and Sale | 629,35 | 2,16k | - |
| 2026-02-14 | Mr. George J. FennellExec. VP of Global CAG Commercial | 255,00 | 0,00 | Derivative Exercise and Retained Stock | - | 10,08k | 2,60% |
| 2026-02-14 | Mr. George J. FennellExec. VP of Global CAG Commercial | -199,00 | 125,24k | Derivative Exercise and Sale | 629,35 | 10,08k | - |
| 2026-02-14 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | 333,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,16k | 8,71% |
| 2026-02-14 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | -123,00 | 77,41k | Derivative Exercise and Sale | 629,35 | 4,16k | - |
| 2026-02-09 | Mr. George J. FennellExec. VP of Global CAG Commercial | 1,48k | 100,15k | Derivative Exercise and Retained Stock | 67,85 | 9,82k | 17,68% |
| 2026-02-10 | Mr. George J. FennellExec. VP of Global CAG Commercial | -11,35k | 6,57M | Derivative Exercise and Sale | 67,85 - 650,32 | 9,82k | - |
| 2025-11-07 | Dr. Nimrata Khatra HuntAdvisor | 3,11k | 896,66k | Derivative Exercise and Retained Stock | 288,78 | 21,31k | 17,06% |
| 2025-11-07 | Dr. Nimrata Khatra HuntAdvisor | -9,43k | 2,74M | Derivative Exercise and Sale | 288,78 - 705,54 | 21,31k | - |
| 2025-08-15 | Mr. Jonathan J. MazelskyExecutive Chairman | -1,05k | 0,00 | Other Disposition | - | 82,44k | -1,26% |
| 2025-09-01 | Mr. Martin Alderson SmithInsider | 13,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,43k | 0,91% |
| 2025-09-01 | Mr. Martin Alderson SmithInsider | -5,00 | 3,24k | Derivative Exercise and Sale | 647,09 | 1,43k | - |
| 2025-08-22 | Ms. M. Anne SzostakInsider | -2,19k | 963,82k | Derivative Exercise and Sale | 206,62 - 647,33 | 1,80k | - |
| 2025-08-22 | Ms. M. Anne SzostakInsider | -259,00 | 0,00 | Other Disposition | - | 1,80k | -12,55% |
| 2025-08-12 | Mr. Michael G. EricksonCEO, President & Director | -405,89 | 263,81k | Verkauf | 649,85 - 649,99 | 11,29k | -3,47% |
| 2025-08-12 | Dr. Nimrata Khatra HuntAdvisor | 1,23k | 299,34k | Derivative Exercise and Retained Stock | 178,26 - 544,08 | 18,19k | 7,23% |
| 2025-08-11 | Dr. Nimrata Khatra HuntAdvisor | -1,20k | 787,84k | Verkauf | 656,53 | 18,19k | -6,19% |
| 2025-08-12 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 183,00 | 99,57k | Derivative Exercise and Retained Stock | 544,08 | 6,34k | 2,97% |
| 2025-08-08 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | -5,45k | 2,42M | Derivative Exercise and Sale | 206,94 - 651,60 | 6,34k | - |
| 2025-08-08 | Mr. Jonathan J. MazelskyExecutive Chairman | 183,00 | 109,52k | Derivative Exercise and Retained Stock | 598,49 | 83,49k | 0,22% |
| 2025-08-07 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | 1,45k | 204,90k | Derivative Exercise and Retained Stock | 141,60 | 3,87k | 59,69% |
| 2025-08-07 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | -402,00 | 204,40k | Derivative Exercise and Sale | 141,60 - 650,06 | 3,87k | - |
| 2025-08-06 | Dr. Nimrata Khatra HuntAdvisor | 5,65k | 962,70k | Derivative Exercise and Retained Stock | 141,60 - 178,26 | 18,17k | 45,15% |
| 2025-08-06 | Dr. Nimrata Khatra HuntAdvisor | -7,14k | 3,07M | Derivative Exercise and Sale | 178,26 - 630,91 | 18,17k | - |
| 2025-08-06 | Mr. Jonathan J. MazelskyExecutive Chairman | -29,26k | 16,51M | Derivative Exercise and Sale | 67,85 - 639,37 | 83,31k | - |
| 2025-08-06 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | -8,41k | 2,96M | Derivative Exercise and Sale | 206,94 - 628,89 | 7,72k | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
